BY HEALTH CAPITAL CONSULTANTS, LLC
***
Supreme Court Hears Oral Arguments on 340B Cuts
On November 30, 2021, the U.S. Supreme Court heard oral arguments regarding the challenges arising from the cuts made by the Centers of Medicare & Medicaid Services (CMS) to the 340B Drug Pricing Program.
The 340B Drug Pricing Program allows hospitals and clinics that treat low-income, medically underserved patients to purchase certain “specified covered outpatient drugs” at discounted prices (applying a ceiling to what drug manufacturers may charge certain healthcare facilities) – 25% to 50% of what providers would typically pay – and then receive reimbursement pursuant to the rates set forth in the Outpatient Prospective Payment System (OPPS) at the same rate as all other providers. (Read more…)
***
HEALTH ECONOMICS CITE: https://www.r2library.com/Resource/Title/0826102549
PODCAST: https://medicalexecutivepost.com/2021/08/27/podcast-hospital-340-b-drug-programs/
***
***
***
***
Filed under: Accounting, Breaking News, Drugs and Pharma, Experts Invited, Videos | Tagged: 340-B Drug Program, Centers of Medicare & Medicaid Services, CMS, CMS drug pricing program, Drugs, Health Capital Consultants LLC, Health Economics, OPPS, Outpatient Prospective Payment System, pharma, pharmacy |
LikeLike